Comparative Pharmacology
Head-to-head clinical analysis: BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN versus BUTAZOLIDIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN versus BUTAZOLIDIN.
BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN vs BUTAZOLIDIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, reducing prostaglandin and thromboxane synthesis, which leads to analgesic, antipyretic, and anti-inflammatory effects.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis. Also has uricosuric effect at higher doses.
500-1000 mg orally every 4-6 hours as needed; maximum 4000 mg in 24 hours.
Butazolidin (phenylbutazone) is typically administered orally at 100-200 mg 3 times daily with meals, not to exceed 600 mg/day. Initial loading dose of 400 mg may be given on day 1, followed by 300-400 mg/day in divided doses. Duration should be limited to 7-10 days.
None Documented
None Documented
Aspirin half-life is 15-20 minutes due to rapid hydrolysis to salicylate. Salicylate terminal half-life is 2-3 hours at low doses, up to 15-30 hours at high doses or with toxicity. At analgesic doses (600-1000 mg), effective half-life is ~3-4 hours, requiring q4-6h dosing.
Terminal half-life: 50-100 hours (prolonged in elderly or hepatic/renal impairment; accumulation risk evident within 5-7 days).
Renal excretion of salicylate and its metabolites (salicyluric acid, salicyl phenolic glucuronide, salicyl acyl glucuronide, gentisic acid). Approximately 90% of a dose is excreted renally; 10% via bile/feces. Excretion is dose- and pH-dependent: alkaline urine increases clearance.
Primarily renal: ~60% as unchanged drug and glucuronide conjugates; biliary/fecal: ~40% (enterohepatic circulation).
Category D/X
Category C
NSAID / Antiplatelet
NSAID